Schedule of Medicamen Organics
| Issue open date | 21 Jun 2024 |
| Issue close date | 25 Jun 2024 |
| UPI mandate deadline | 25 Jun 2024 (5 PM) |
| Allotment finalization | 26 Jun 2024 |
| Refund initiation | 27 Jun 2024 |
| Share credit | 27 Jun 2024 |
| Listing date | 28 Jun 2024 |
| Mandate end date | 10 Jul 2024 |
| Lock-in end date for anchor investors (50%) | 25 Jul 2024 |
| Lock-in end date for anchor investors (remaining) | 23 Sep 2024 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Medicamen Organics
Incorporated in 1995, Medicamen Organics is engaged in developing, manufacturing, and distributing a broad range of pharmaceutical dosages including generic dosages in the form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension, and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer.
The company’s product portfolio consists of 84 products and comprises of wide range of drugs like, Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Proton Pump Inhibitors, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral and Non- steroidal anti-inflammatory drug (NSAIDs).
It is an ISO 9001:2015 certified company with its products marketed across India as well as African, CIS, and South East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by its third-party distributor.
Financials of Medicamen Organics
Issue size
| Funds Raised in the IPO | Amount |
| Overall | ₹10.54 crores |
| Fresh Issue | ₹10.54 crores |
| Offer for sale | – |
*All figures except EPS are in ₹ Crores
Risks
- Client concentration risk: The company relies heavily on a limited number of customers, with the top ten customers accounting for 78.76%, 62%, and 66.45% of total sales for the financial years ending on March 31, 2024, 2023, and 2022, respectively. The potential loss of any of these major clients could impact both revenues and profitability.
- Counterfeit medications: The presence of counterfeit drugs, including products falsely represented as originating from the company, has the potential to harm the company’s reputation and operational performance.
Note:
- The above schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion.
- The allotment status will be available by June 27, 2024, on the Registrar’s website and the NSE website.